Published: November 2017 | Report Code: LS11275 | Available Format: PDF | Pages: 157
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation
Acne vulgaris develops on the face and upper trunk and most often affects adolescents. The causes of the acne include excess oil production, clogging of air follicles by oil and dead skin cells, and excess activity of androgens. The clinical presentation of acne vulgaris ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back.
ACNE VULGARIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
According to the American Academy of Dermatology (AAD), acne vulgaris has a prevalence of over 90% in the population between 10 to 20 years, and a point-prevalence of approximately 85% in the population between 15 to 24 years, globally. In 2016, in the U.S., the cost of acne vulgaris was above $3 billion per year in terms of treatment and loss of productivity. Sol-Gel Technologies Ltd. is in the process of research and development of three products for the treatment of acne vulgaris. PR023 is in early stages of development by the Realm Therapeutics, Inc. for the treatment of acne vulgaris. Increased early stage drug candidates and positive clinical trial results of the drugs being developed by the different pharmaceutical companies, are the major drivers for the acne vulgaris pipeline.
As of November 2017, the acne vulgaris therapeutics pipeline comprises of 49 drug candidates in different stages of development.
Acne vulgaris epidemiology analysis forecasts an increase in the total number of prevalent cases in population aged between 10 to 45 years in the 7MM, from 166 million cases in 2016 to 178 million cases in 2023.
ACNE VULGARIS THERAPEUTICS TREATMENT USAGE PATTERN IN 7MM (2016-2023)
Some of the players developing drugs for the treatment of acne vulgaris include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws